Home
Sign In
About
Curriculum
Activity Information
Target Audience
Learning Objectives
Technical Requirements
The Curriculum in Iron Metabolism & Related Disorders is supported by an educational grant from
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Course materials have been developed for use outside of the United States.
|
 |
|
|
|
|
|
|
Molecular Pathophysiology of Iron Disorders
Recent studies have significantly advanced our understanding of the pathophysiology of iron dysregulation, providing new insights into the central role of hepcidin/ferroportin interactions in this process. In this webcast, 2 international experts in the field discuss this exciting information and its relevance to the potential development of iron dysregulation—including iron-loading anaemias, hereditary haemochromatosis, and anaemia of inflammation as well as iron-refractory iron-deficiency anaemia.
|
|
Faculty
|
|
|
Tom Ganz, PhD, MD
Professor of Medicine and
Pathology
David Geffen
School of Medicine,
University of California,
Los Angeles, CA
|
|
|
|
Chaim Hershko, MD
Professor Emeritus
Shaare Zedek Medical
Center
Jerusalem, Israel
|
|
|
Target Audience
This activity is designed for haematologists, medical oncologists, haematology-oncology specialists, and other healthcare professionals involved in the screening, evaluation, treatment, and management of adults and children with iron overload, resulting from the spectrum of chronic iron overload diseases.
|
Learning Objectives
After participating in this activity, participants should be better able to:
- Based on current understanding of interactions between hepcidin, ferroportin, and the iron responsive element – iron regulatory protein (IRE-IRP), asses the mechanisms contributing to the pathophysiology of iron dysregulation in patients with hereditary haemochromatosis, iron-loading anaemias (including B-thalassaemia), anaemia of inflammation, and iron-refractory iron-deficient anaemia (IRIDA).
|
Disclosure Information
Tom Ganz, PhD, MD, has received grant/research support from Amgen Pharmaceuticals and Novartis Pharmaceuticals. He is a consultant for Xenon Pharmaceuticals; and is on the advisory board for Intrinsic LifeSciences LLC. He is a shareholder for Intrinsic LifeSciences LLC and
Xenon Pharmaceuticals.
Chaim Hershko, MD, has no significant relationships to disclose.
|
|
|
|
|
|
|
